Head-To-Head Analysis: ADVANZ PHARMA (OTCMKTS:CXRXF) versus Syros Pharmaceuticals (NASDAQ:SYRS)

Valuation and Earnings

This table compares Syros Pharmaceuticals and ADVANZ PHARMA”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386,000.00	0.01	-$164.57 million	($3.03)	0.00
ADVANZ PHARMA	$525.58 million	1.59	-$74.86 million	N/A	N/A

ADVANZ PHARMA has higher revenue and earnings than Syros Pharmaceuticals.

Profitability

This table compares Syros Pharmaceuticals and ADVANZ PHARMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
ADVANZ PHARMA	-15.31%	N/A	-4.38%

Insider and Institutional Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ADVANZ PHARMA beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

About ADVANZ PHARMA

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.